within Pharmacolibrary.Drugs.ATC.N;

model N02BG08
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 2.3333333333333336e-06,
    adminDuration  = 600,
    adminMass      = 1.2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00026000000000000003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N02BG08</td></tr><td>route:</td><td>intrathecal</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ziconotide is a synthetic peptide derived from the venom of the marine cone snail Conus magus. It is a selective blocker of N-type voltage-gated calcium channels and is used for the management of severe chronic pain in patients who require intrathecal therapy and for whom other treatments have proven inadequate. Ziconotide is approved by the FDA for intrathecal administration in refractory chronic pain.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients with severe chronic pain receiving intrathecal ziconotide.</p><h4>References</h4><ol><li><p>McDowell, GC, &amp; Pope, JE (2016). Intrathecal Ziconotide: Dosing and Administration Strategies in Patients With Refractory Chronic Pain. <i>Neuromodulation : journal of the International Neuromodulation Society</i> 19(5) 522–532. DOI:<a href=&quot;https://doi.org/10.1111/ner.12392&quot;>10.1111/ner.12392</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26856969/&quot;>https://pubmed.ncbi.nlm.nih.gov/26856969</a></p></li><li><p>Wermeling, D, et al., &amp; Chao, S (2003). Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. <i>Journal of clinical pharmacology</i> 43(6) 624–636. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12817525/&quot;>https://pubmed.ncbi.nlm.nih.gov/12817525</a></p></li><li><p>Sanford, M (2013). Intrathecal ziconotide: a review of its use in patients with chronic pain refractory to other systemic or intrathecal analgesics. <i>CNS drugs</i> 27(11) 989–1002. DOI:<a href=&quot;https://doi.org/10.1007/s40263-013-0107-5&quot;>10.1007/s40263-013-0107-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23999971/&quot;>https://pubmed.ncbi.nlm.nih.gov/23999971</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N02BG08;
